Mucosal immunity and HIV/AIDS vaccines. Report of an International Workshop, 28-30 October 2007

Vaccine

Volumn 26, Issue 32, 2008, Pages 3969-3977

  Girard, Marc P ^a   Bansal, Geetha P ^b   Pedroza Martins, Livia ^c   Dodet, Betty ^d   Mehra, Vijay ^b   Schito, Marco ^b   Mathieson, Bonnie ^e   Delfraissy, Jean François ^c   Bradac, James ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c ANRS   (France)

^d Dodet Bioscience   (France)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHOLERA VACCINE; GAMMA INTERFERON; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HERPES VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; TYPHOID VACCINE;

ANTIBODY RESPONSE; B LYMPHOCYTE ACTIVATION; CONFERENCE PAPER; DRUG DESIGN; DRUG RESEARCH; GENDER; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; INFECTION PREVENTION; INTERFERON PRODUCTION; MUCOSA; NONHUMAN; POSTGRADUATE EDUCATION; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE ACTIVATION; VACCINATION; VIRUS TRANSMISSION;

AIDS VACCINES; ANIMALS; DRUG EVALUATION, PRECLINICAL; HIV; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; IMMUNITY, MUCOSAL;

EID: 47349114361     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.04.051     Document Type: Conference Paper

References (67)

1. Mehandru S., Poles M.A., Tenner-Racz K., Horowitz A., Hurley A., Hogan C., et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 200 6 (2004) 761-770
2. Holmgren J., and Czerkinsky C. Mucosal immunity and vaccines. Nat Med 11 4 Suppl. (2005) S45-53
3. Cuburu N., Kweon M.N., Song J.H., Hervouet C., Luci C., Sun J.B., et al. Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 25 51 (2007) 8598-8610
4. Adamsson J., Lindblad M., Lundqvist A., Kelly D., Holmgren J., and Harandi A.M. Novel immunostimulatory agent based on CpG oligodeoxynucleotide linked to the nontoxic B subunit of cholera toxin. J Immunol 176 8 (2006) 4902-4913
5. Mora J.R., Cheng G., Picarella D., Briskin M., Buchanan N., and von Andrian U.H. Reciprocal and dynamic control of CD8 T cell homing by dendritic cells from skin- and gut-associated lymphoid tissues. J Exp Med 201 2 (2005) 303-316
6. Mora J.R., and von Andrian U.H. T-cell homing specificity and plasticity: new concepts and future challenges. Trends Immunol 27 5 (2006) 235-243
7. Iliev I.D., Matteoli G., and Rescigno M. The yin and yang of intestinal epithelial cells in controlling dendritic cell function. J Exp Med 204 10 (2007) 2253-2257
8. Le Borgne M., Etchart N., Goubier A., Lira S.A., Sirard J.C., van Rooijen N., et al. Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo. Immunity 24 2 (2006) 191-201
9. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 25 30 (2007) 5467-5484
10. Mennechet F.J., Kasper L.H., Rachinel N., Minns L.A., Luangsay S., Vandewalle A., et al. Intestinal intraepithelial lymphocytes prevent pathogen-driven inflammation and regulate the Smad/T-bet pathway of lamina propria CD4+ T cells. Eur J Immunol 34 4 (2004) 1059-1067
11. Ostman S., Taube M., and Telemo E. Tolerosome-induced oral tolerance is MHC dependent. Immunology 116 4 (2005) 464-476
12. Epple H.J., Loddenkemper C., Kunkel D., Troger H., Maul J., Moos V., et al. Mucosal but not peripheral FOXP3+ regulatory T cells are highly increased in untreated HIV infection and normalize after suppressive HAART. Blood 108 9 (2006) 3072-3078
13. Hladik F., Sakchalathorn P., Ballweber L., Lentz G., Fialkow M., Eschenbach D., et al. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 26 2 (2007) 257-270
14. Alfsen A., Yu H., Magerus-Chatinet A., Schmitt A., and Bomsel M. HIV-1-infected blood mononuclear cells form an integrin- and agrin-dependent viral synapse to induce efficient HIV-1 transcytosis across epithelial cell monolayer. Mol Biol Cell 16 9 (2005) 4267-4279
15. Amerongen H.M., Weltzin R., Farnet C.M., Michetti P., Haseltine W.A., and Neutra M.R. Transepithelial transport of HIV-1 by intestinal M cells: a mechanism for transmission of AIDS. J Acquir Immune Defic Syndr 4 8 (1991) 760-765
16. Bomsel M., and Alfsen A. Entry of viruses through the epithelial barrier: pathogenic trickery. Nat Rev Mol Cell Biol 4 1 (2003) 57-68
17. Fotopoulos G., Harari A., Michetti P., Trono D., Pantaleo G., and Kraehenbuhl J.P. Transepithelial transport of HIV-1 by M cells is receptor-mediated. Proc Natl Acad Sci USA 99 14 (2002) 9410-9414
18. Fahrbach K.M., Barry S.M., Ayehunie S., Lamore S., Klausner M., and Hope T.J. Activated CD34-derived Langerhans cells mediate transinfection with human immunodeficiency virus. J Virol 81 13 (2007) 6858-6868
19. Auvert B., Taljaard D., Lagarde E., Sobngwi-Tambekou J., Sitta R., and Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2 11 (2005) e298
20. Weiss H.A. Male circumcision as a preventive measure against HIV and other sexually transmitted diseases. Curr Opin Infect Dis 20 1 (2007) 66-72
21. Smith P.D., Ochsenbauer-Jambor C., and Smythies L.E. Intestinal macrophages: unique effector cells of the innate immune system. Immunol Rev 206 (2005) 149-159
22. Veazey R.S., DeMaria M., Chalifoux L.V., Shvetz D.E., Pauley D.R., Knight H.L., et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 280 5362 (1998) 427-431
23. Poles M.A., Elliott J., Taing P., Anton P.A., and Chen I.S. A preponderance of CCR5(+) CXCR4(+) mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection. J Virol 75 18 (2001) 8390-8399
24. Brenchley J.M., Schacker T.W., Ruff L.E., Price D.A., Taylor J.H., Beilman G.J., et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 200 6 (2004) 749-759
25. Cumont M.C., Monceaux V., Viollet L., Lay S., Parker R., Hurtrel B., et al. TGF-beta in intestinal lymphoid organs contributes to the death of armed effector CD8 T cells and is associated with the absence of virus containment in rhesus macaques infected with the simian immunodeficiency virus. Cell Death Differ 14 10 (2007) 1747-1758
26. Brenchley J.M., Price D.A., and Douek D.C. HIV disease: fallout from a mucosal catastrophe?. Nat Immunol 7 3 (2006) 235-239
27. Gordon S.N., Klatt N.R., Bosinger S.E., Brenchley J.M., Milush J.M., Engram J.C., et al. Severe depletion of mucosal CD4+ T cells in AIDS-free simian immunodeficiency virus-infected sooty mangabeys. J Immunol 179 5 (2007) 3026-3034
28. Silvestri G., Paiardini M., Pandrea I., Lederman M.M., and Sodora D.L. Understanding the benign nature of SIV infection in natural hosts. J Clin Invest 117 11 (2007) 3148-3154
29. Barry A.P., Silvestri G., Safrit J.T., Sumpter B., Kozyr N., McClure H.M., et al. Depletion of CD8+ cells in sooty mangabey monkeys naturally infected with simian immunodeficiency virus reveals limited role for immune control of virus replication in a natural host species. J Immunol 178 12 (2007) 8002-8012
30. Pope M., and Haase A.T. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med 9 7 (2003) 847-852
31. Haase A.T. Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 5 10 (2005) 783-792
32. Parker C.E., Deterding L.J., Hager-Braun C., Binley J.M., Schulke N., Katinger H., et al. Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5. J Virol 75 22 (2001) 10906-10911
33. Kozlowski P.A., Lynch R.M., Patterson R.R., Cu-Uvin S., Flanigan T.P., and Neutra M.R. Modified wick method using Weck-Cel sponges for collection of human rectal secretions and analysis of mucosal HIV antibody. J Acquir Immune Defic Syndr 24 4 (2000) 297-309
34. Dubey S., Clair J., Fu T.M., Guan L., Long R., Mogg R., et al. Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay. J Acquir Immune Defic Syndr 45 1 (2007) 20-27
35. Letvin N.L., Mascola J.R., Sun Y., Gorgone D.A., Buzby A.P., Xu L., et al. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 312 5779 (2006) 1530-1533
36. HIV vaccine failure prompts Merck to halt trial. Nature 2007;449(7161):390.
37. Zhou Q., Hidajat R., Peng B., Venzon D., Aldrich M.K., Richardson E., et al. Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251). Vaccine 25 47 (2007) 8021-8035
38. Abel K., Compton L., Rourke T., Montefiori D., Lu D., Rothaeusler K., et al. Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses. J Virol 77 5 (2003) 3099-3118
39. Critchfield J.W., Lemongello D., Walker D.H., Garcia J.C., Asmuth D.M., Pollard R.B., et al. Multifunctional human immunodeficiency virus (HIV) gag-specific CD8+ T-cell responses in rectal mucosa and peripheral blood mononuclear cells during chronic HIV type 1 infection. J Virol 81 11 (2007) 5460-5471
40. Saez-Cirion A., Lacabaratz C., Lambotte O., Versmisse P., Urrutia A., Boufassa F., et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci USA 104 16 (2007) 6776-6781
41. Belyakov I.M., Kuznetsov V.A., Kelsall B., Klinman D., Moniuszko M., Lemon M., et al. Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa. Blood 107 8 (2006) 3258-3264
42. Belyakov I.M., Isakov D., Zhu Q., Dzutsev A., and Berzofsky J.A. A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells. J Immunol 178 11 (2007) 7211-7221
43. Saif L.J. Animal coronavirus vaccines: lessons for SARS. Dev Biol (Basel) 119 (2004) 129-140
44. Eo S.K., Gierynska M., Kamar A.A., and Rouse B.T. Prime-boost immunization with DNA vaccine: mucosal route of administration changes the rules. J Immunol 166 9 (2001) 5473-5479
45. Bomsel M., Pastori C., Tudor D., Alberti C., Garcia S., Ferrari D., et al. Natural mucosal antibodies reactive with first extracellular loop of CCR5 inhibit HIV-1 transport across human epithelial cells. Aids 21 1 (2007) 13-22
46. Barassi C., Soprana E., Pastori C., Longhi R., Buratti E., Lillo F., et al. Induction of murine mucosal CCR5-reactive antibodies as an anti-human immunodeficiency virus strategy. J Virol 79 11 (2005) 6848-6858
47. Arbyn M., and Dillner J. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. J Clin Virol 38 3 (2007) 189-197
48. Villa L.L., Ault K.A., Giuliano A.R., Costa R.L., Petta C.A., Andrade R.P., et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 24 27-28 (2006) 5571-5583
49. Nardelli-Haefliger D., Wirthner D., Schiller J.T., Lowy D.R., Hildesheim A., Ponci F., et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 95 15 (2003) 1128-1137
50. Johansson E.L., Wassen L., Holmgren J., Jertborn M., and Rudin A. Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect Immun 69 12 (2001) 7481-7486
51. Kozlowski P.A., Williams S.B., Lynch R.M., Flanigan T.P., Patterson R.R., Cu-Uvin S., et al. Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J Immunol 169 1 (2002) 566-574
52. Rudin A., Johansson E.L., Bergquist C., and Holmgren J. Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans. Infect Immun 66 7 (1998) 3390-3396
53. Nardelli-Haefliger D., Lurati F., Wirthner D., Spertini F., Schiller J.T., Lowy D.R., et al. Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. Vaccine 23 28 (2005) 3634-3641
54. Buonaguro L., Devito C., Tornesello M.L., Schroder U., Wahren B., Hinkula J., et al. DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. Vaccine 25 32 (2007) 5968-5977
55. Vajdy M. Current efforts on generation of optimal immune responses against HIV through mucosal immunisations. Drugs R D 7 5 (2006) 267-288
56. Stanberry L.R., Spruance S.L., Cunningham A.L., Bernstein D.I., Mindel A., Sacks S., et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 347 21 (2002) 1652-1661
57. Patterson L.J., Malkevitch N., Venzon D., Pinczewski J., Gomez-Roman V.R., Wang L., et al. Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol 78 5 (2004) 2212-2221
58. Malkevitch N.V., Patterson L.J., Aldrich M.K., Wu Y., Venzon D., Florese R.H., et al. Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses. Virology 353 1 (2006) 83-98
59. Matoba N., Magerus A., Geyer B.C., Zhang Y., Muralidharan M., Alfsen A., et al. A mucosally targeted subunit vaccine candidate eliciting HIV-1 transcytosis-blocking Abs. Proc Natl Acad Sci USA 101 37 (2004) 13584-13589
60. Pialoux G., Hocini H., Perusat S., Silberman B., Salmon-Ceron D., Slama L., et al. Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: The ANRS VAC14 study. Vaccine 26 21 (2007) 2657-2666
61. Casimiro D.R., Wang F., Schleif W.A., Liang X., Zhang Z.Q., Tobery T.W., et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag. J Virol 79 24 (2005) 15547-15555
62. McDermott A.B., O'Connor D.H., Fuenger S., Piaskowski S., Martin S., Loffredo J., et al. Cytotoxic T-lymphocyte escape does not always explain the transient control of simian immunodeficiency virus SIVmac239 viremia in adenovirus-boosted and DNA-primed Mamu-A*01-positive rhesus macaques. J Virol 79 24 (2005) 15556-15566
63. Loffredo J.T., Maxwell J., Qi Y., Glidden C.E., Borchardt G.J., Soma T., et al. Mamu-B*08-positive macaques control simian immunodeficiency virus replication. J Virol 81 16 (2007) 8827-8832
64. Loffredo J.T., Burwitz B.J., Rakasz E.G., Spencer S.P., Stephany J.J., Vela J.P., et al. The antiviral efficacy of simian immunodeficiency virus-specific CD8+ T cells is unrelated to epitope specificity and is abrogated by viral escape. J Virol 81 6 (2007) 2624-2634
65. Valentine L.E., Piaskowski S.M., Rakasz E.G., Henry N.L., Wilson N.A., and Watkins D.I. Recognition of escape variants in ELISPOT does not always predict CD8+ T-cell recognition of simian immunodeficiency virus-infected cells expressing the same variant sequences. J Virol 82 1 (2008) 575-581
66. Mansfield K., Lang S.M., Gauduin M.C., Sanford H.B., Lifson J.D., Johnson R.P., et al. Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery. J Virol 82 8 (2008) 4135-4148
67. D'Souza M.P., and Altfeld M. Measuring HIV-1-specific T cell immunity: how valid are current assays?. J Infect Dis 197 3 (2008) 337-339